Bethany Pitcher
Mississauga, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 13, 2022
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC.
Journal: JTO clinical and research reports
Published: April 21, 2022
Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non-Small Cell Lung Cancer.
Journal: Molecular cancer research : MCR
Published: March 01, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 08, 2021
Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 05, 2020
Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers.
Journal: Cancer discovery
Published: October 25, 2019
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 29, 2019
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study.
Journal: JCO precision oncology
Published: February 25, 2019
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 24, 2018
Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study.
Journal: JCO precision oncology
Published: August 31, 2018
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
Journal: JAMA oncology
Published: December 01, 2017
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 22, 2017
Last Updated: 09/26/2026